MedPath

Nutritional Intervention During Gestation and Offspring Health

Not Applicable
Completed
Conditions
Maternal Glycemia
Interventions
Other: Nutritional Supplement
Other: Standard of Care
Registration Number
NCT02285764
Lead Sponsor
Abbott Nutrition
Brief Summary

The purpose of this study is to investigate the potential effects of a modified carbohydrate nutritional product for obese pregnant women to reduce maternal glycemia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
331
Inclusion Criteria
  • Voluntarily signed and dated an ICF, approved by an IEC/IRB and provided applicable privacy authorization prior to any participation in the study.
  • Obese (BMI ≥ 30) as determined by pre-pregnancy BMI.
  • ≥18 years of age.
  • ≥15+0 but ≤16+6 weeks gestation with a singleton pregnancy.
  • Willing to follow supplementation protocol and follow appropriate nutritional guidance and refrain from consuming other caloric nutritional supplements that are not approved by the study staff, if applicable.
  • Willing to provide body composition measures on infant at birth.
  • Willing to consider additional measures if follow-up studies are conducted.
Exclusion Criteria
  • Adverse maternal and/or fetal medical history which is expected to alter blood glucose regulations.
  • Previously diagnosed diabetes, previous gestational diabetes, systemic lupus erythematodes, anti-phospholipid syndrome, known renal disease, treated hypertension, uncontrolled hypothyroidism and/or cancer.
  • Taking medications that can impact blood glucose.
  • Previous bariatric surgery.
  • Lactose intolerant and/or has milk protein allergy or requires a special diet regime.
  • Participating in another clinical trial that would impact participation in this study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nutritional SupplementNutritional SupplementOne 237 ml oral supplement consumed two times a day; Not commercially available.
Standard of CareStandard of CareAs determined by the study site
Primary Outcome Measures
NameTimeMethod
Maternal Oral Glucose Tolerance Test (OGTT)27-28 weeks gestation

2 hour OGTT

Secondary Outcome Measures
NameTimeMethod
Maternal Fasting Blood Glucose34-36 weeks gestation
Neonatal Body CompositionBirth - 72 hours

Trial Locations

Locations (3)

Ludwig-Maximilians-University of Munich, Dr. von Hauner Children's Hospital

🇩🇪

München, Germany

University Clinical Hospital San Cecilio

🇪🇸

Granada, Spain

University of Granda

🇪🇸

Granada, Spain

© Copyright 2025. All Rights Reserved by MedPath